Research ArticleArticle
Open Access
Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT
Philip J. Mease, Michele Heckaman, Sonja Kary and Hartmut Kupper
The Journal of Rheumatology March 2013, jrheum.120970; DOI: https://doi.org/10.3899/jrheum.120970
Philip J. Mease
From the Swedish Medical Center and University of Washington, Seattle, Washington; Abbott, AbbVie Inc., North Chicago, Illinois, USA; and AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. Supported by AbbVie Inc. Dr. Mease has received consulting fees and research grants from AbbVie and has participated in speakers bureaus on behalf of AbbVie. M. Heckaman and H. Kupper are AbbVie employees who may hold stock or stock options in AbbVie. P.J. Mease, MD, Clinical Professor, Swedish Medical Center and University of Washington; M. Heckaman, MS, Statistical Analyst, AbbVie, USA; S. Kary, MD, Immunoscience Division; H. Kupper, MD, Senior Medical Director, Immunology, AbbVie Deutschland GmbH & Co. KG. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. E-mail: pmease@philipmease.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication January 16, 2013.
Michele Heckaman
From the Swedish Medical Center and University of Washington, Seattle, Washington; Abbott, AbbVie Inc., North Chicago, Illinois, USA; and AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. Supported by AbbVie Inc. Dr. Mease has received consulting fees and research grants from AbbVie and has participated in speakers bureaus on behalf of AbbVie. M. Heckaman and H. Kupper are AbbVie employees who may hold stock or stock options in AbbVie. P.J. Mease, MD, Clinical Professor, Swedish Medical Center and University of Washington; M. Heckaman, MS, Statistical Analyst, AbbVie, USA; S. Kary, MD, Immunoscience Division; H. Kupper, MD, Senior Medical Director, Immunology, AbbVie Deutschland GmbH & Co. KG. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. E-mail: pmease@philipmease.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication January 16, 2013.
Sonja Kary
From the Swedish Medical Center and University of Washington, Seattle, Washington; Abbott, AbbVie Inc., North Chicago, Illinois, USA; and AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. Supported by AbbVie Inc. Dr. Mease has received consulting fees and research grants from AbbVie and has participated in speakers bureaus on behalf of AbbVie. M. Heckaman and H. Kupper are AbbVie employees who may hold stock or stock options in AbbVie. P.J. Mease, MD, Clinical Professor, Swedish Medical Center and University of Washington; M. Heckaman, MS, Statistical Analyst, AbbVie, USA; S. Kary, MD, Immunoscience Division; H. Kupper, MD, Senior Medical Director, Immunology, AbbVie Deutschland GmbH & Co. KG. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. E-mail: pmease@philipmease.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication January 16, 2013.
Hartmut Kupper
From the Swedish Medical Center and University of Washington, Seattle, Washington; Abbott, AbbVie Inc., North Chicago, Illinois, USA; and AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. Supported by AbbVie Inc. Dr. Mease has received consulting fees and research grants from AbbVie and has participated in speakers bureaus on behalf of AbbVie. M. Heckaman and H. Kupper are AbbVie employees who may hold stock or stock options in AbbVie. P.J. Mease, MD, Clinical Professor, Swedish Medical Center and University of Washington; M. Heckaman, MS, Statistical Analyst, AbbVie, USA; S. Kary, MD, Immunoscience Division; H. Kupper, MD, Senior Medical Director, Immunology, AbbVie Deutschland GmbH & Co. KG. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. E-mail: pmease@philipmease.com Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication January 16, 2013.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT
Philip J. Mease, Michele Heckaman, Sonja Kary, Hartmut Kupper
The Journal of Rheumatology Mar 2013, jrheum.120970; DOI: 10.3899/jrheum.120970